Ousia - great post. Well thought out.
PI-88 Trials in Taiwan are a much more 'straightforward' proposition then the Multi Country Phase III undertaking.
Recruitment rates are very difficult to predict in terms of such global Trial. Liver Cancer is a much more prevalent disease in Asia as I understand matters, and therefore recruitment rates are more certain there.
A new dawn for Progen!